Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 347

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 347
---
LENTS

                                December 31,                             
                                December 31,                             
                                2023                                     
                                2023                                     
 ─────────────────────────────────────────────────────────────────────────
                                in USD thousands                         
  Cash on hand and in bank                            3,154      944     
  Short-term bank deposits                            1,101      9,492   
                                                      4,255      10,436  

The short-term bank deposits included in cash and cash equivalents bear interest at annual rates of between0.70% and5.66%.

F - 26

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - SHORT-TERM BANK DEPOSITS
The short-term bank deposits are primarily in dollars and bear interest at annual rates of between4.20% and6.63%.

NOTE 7 - INVENTORY

                        December 31,                            
                        December 31,                            
                        2023                                    
                        2023                                    
 ────────────────────────────────────────────────────────────────
                        in USD thousands                        
  Raw materials                               903        -      
  Work-in-progress                            471        2,980  
  Finished goods                              579        165    
                                              1,953      3,145  

F - 27

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 - PROPERTY AND EQUIPMENT
Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications:
Cost Accumulated depreciation
Balance at Balance at
beginning beginning
of year of year
in USD thousands in USD thousands
Composition in 2024
Office furniture and equipment 252 251 165 191 87
Computers and communications equipment 1,062 467 820 291 242
Laboratory equipment 1,613 1,571 1,598 1,525 15
Leasehold improvements 2,036 2,036 1,907 1,932 129
4,963 4,325 4,490 3,939 473

F - 28

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 - INTANGIBLE ASSETS
Intellectual property included the following intangible assets acquired by the Company:
$ 6.7 million originally recorded as a result of the acquisition of Agalimmune